Sequential biocatalytic resolution of (±)-trans-cyclohexane-1,2-diamine. Chemoenzymatic synthesis of an optically active polyamine
摘要:
Candida antarctica lipase-catalysed double monoaminolysis of dimethyl malonate by (+/-)-trans-cyclohexane-1,2-diamine allows the sequential resolution of the latter compound, affording an enantiopure bis(amidoester), (R,R)-3, which is subsequently transformed into an optically active polyamine, (R,R)-9.
Double Chirality Transmission in Trityl Amines: Sensing Molecular Dynamic Stereochemistry by Circular Dichroism and DFT Calculations
作者:Jacek Ściebura、Jacek Gawroński
DOI:10.1002/chem.201101699
日期:2011.11.18
than the methyl group (L). This is the case when a CD‐active trityl group at the nitrogen atom is used to report the chirality of the carbon substituent with two different sized groups (see scheme). The use of the trityl CD sensor allowed, in addition, the determination of the dominant absolute configuration of the nitrogen atom in chiralamines.
Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
申请人:MONSANTO COMPANY
公开号:EP1420022A1
公开(公告)日:2004-05-19
The present invention relates to compounds which are effective as catalysts for dismutating superoxide and, more particularly, the manganese or iron complexes of substituted, unsaturated heterocyclic pentaazacyclopentadecane ligands which catalytically dismutate superoxide.
Substituted pyridino pentaazamacrocyle ligands having superoxide dismutase activity
申请人:MONSANTO COMPANY
公开号:EP1420019A1
公开(公告)日:2004-05-19
The present invention relates to macrocyclic organic unchelated ligands having the following formula:
本发明涉及具有下式的大环有机无螯配体:
Biomaterials modified with superoxide dismutase mimics
申请人:Monsanto Company
公开号:EP1577313A1
公开(公告)日:2005-09-21
The present invention relates to biomaterials modified with non-proteinaceous catalysts for the dismutation of superoxide, and processes for making such materials. This modification may be by covalent conjugation, copolymerization, or admixture of the non-proteinaceous catalyst with the biomaterial. The resulting modified biomaterials exhibit a marked decrease in inflammatory response and subsequent degradation when placed in contact with vertebrate biological systems.
The present invention relates to hyaluronic acid polymers modified with non-proteinaceous catalysts for the dismutation of superoxide, and processes for making such materials. The invention further provides pharmaceutical compositions comprising the modified biopolymer and therapeutic methods comprising administering the modified biopolymer to a subject in need thereof.